These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 29912274)
1. Selective RET kinase inhibition for patients with RET-altered cancers. Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274 [TBL] [Abstract][Full Text] [Related]
2. Precision Targeted Therapy with BLU-667 for Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135 [TBL] [Abstract][Full Text] [Related]
3. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307 [TBL] [Abstract][Full Text] [Related]
4. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208 [TBL] [Abstract][Full Text] [Related]
5. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000 [TBL] [Abstract][Full Text] [Related]
6. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198 [TBL] [Abstract][Full Text] [Related]
7. RET fusions in solid tumors. Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421 [TBL] [Abstract][Full Text] [Related]
8. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative. Kumarasamy VM; Sun D Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409 [TBL] [Abstract][Full Text] [Related]
9. Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid. Kander EM; Shah MH; Zhou Y; Goyal A; Palmer JD; Owen DH; Shilo K; Patel G; Raval RR; Gonzalez J; Nguyen M; Olek E; Kherani J; Rothenberg SM; Konda B Clin Lung Cancer; 2021 May; 22(3):e442-e445. PubMed ID: 32660930 [No Abstract] [Full Text] [Related]
11. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056 [TBL] [Abstract][Full Text] [Related]
12. Pralsetinib: First Approval. Markham A Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236 [TBL] [Abstract][Full Text] [Related]
13. Selpercatinib. Am J Health Syst Pharm; 2020 Oct; 77(22):1818-1821. PubMed ID: 32930710 [No Abstract] [Full Text] [Related]
14. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy. Bruce JY; Bible KC; Chintakuntlawar AV Thyroid; 2021 Feb; 31(2):332-333. PubMed ID: 32664802 [No Abstract] [Full Text] [Related]
15. Landscape of Acquired Resistance to Osimertinib in Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ Oncology; 2016; 90(6):339-46. PubMed ID: 27207748 [TBL] [Abstract][Full Text] [Related]
17. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With Kim J; Bradford D; Larkins E; Pai-Scherf LH; Chatterjee S; Mishra-Kalyani PS; Wearne E; Helms WS; Ayyoub A; Bi Y; Sun J; Charlab R; Liu J; Zhao H; Liang D; Ghosh S; Philip R; Pazdur R; Theoret MR; Beaver JA; Singh H Clin Cancer Res; 2021 Oct; 27(20):5452-5456. PubMed ID: 34045295 [TBL] [Abstract][Full Text] [Related]
18. RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm. Saleh K; Khalife N; Felefly T Future Oncol; 2021 Apr; 17(12):1445-1448. PubMed ID: 33573417 [No Abstract] [Full Text] [Related]
19. Efficacy of Selpercatinib in Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S; Godbert Y; Barlesi F; Morris JC; Owonikoko TK; Tan DSW; Gautschi O; Weiss J; de la Fouchardière C; Burkard ME; Laskin J; Taylor MH; Kroiss M; Medioni J; Goldman JW; Bauer TM; Levy B; Zhu VW; Lakhani N; Moreno V; Ebata K; Nguyen M; Heirich D; Zhu EY; Huang X; Yang L; Kherani J; Rothenberg SM; Drilon A; Subbiah V; Shah MH; Cabanillas ME N Engl J Med; 2020 Aug; 383(9):825-835. PubMed ID: 32846061 [TBL] [Abstract][Full Text] [Related]
20. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]